Multisystem Organ Failure of Sepsis

Multisystem Organ Failure of Sepsis


 

NTRODUCTION


Background: In 1914, Schottmueller wrote, "Septicemia is a state of microbial invasion from a portal of entry into the blood stream which causes sign of illness." The definition did not change significantly over the years because sepsis and septicemia were considered to refer to a number of ill-defined clinical conditions in addition to bacteriemia. In practice, the terms often were used interchangeably; however, less than one half of the patients who have signs and symptoms of sepsis have positive blood cultures.

In the late 1960s, several reports appeared describing remote organ failure (eg, pulmonary failure, liver failure) as a complication of severe sepsis. In 1975, a classic editorial by Baue was entitled "Multiple, progressive or sequential systems failure, a syndrome of the 1970s." This concept was formulated as the basis of a new clinical syndrome. Several terms were cloned thereafter, such as multiple organ failure, multiple system organ failure, and multiple organ system failure, to describe this evolving clinical syndrome of otherwise unexplained progressive physiological failure of several interdependent organ systems. More recently, the term multiple organ dysfunction syndrome (MODS) has been proposed as a more appropriate description.

Multiorgan failure from sepsis

Sepsis is a clinical syndrome that complicates severe infection and is characterized by systemic inflammation and widespread tissue injury. In this syndrome, tissue is removed from the original insult that displayed the signs of inflammation, such as vasodilatation, increased microvascular permeability, and leukocyte accumulation. Multiple organ dysfunction is a continuum, with incremental degrees of physiological derangements in individual organs; it is a process rather than an event. Alteration in organ function can vary widely from a mild degree of organ dysfunction to frank organ failure. The degree of organ dysfunction has a major clinical impact. The term MODS is defined as a clinical syndrome in which the development of progressive and potentially reversible physiological dysfunction in 2 or more organs or organ systems induced by a variety of acute insults, including sepsis, is characteristic.

In 1991, the American College of Chest Physicians/Society of Critical Care Medicine Consensus Panel developed definitions of the various stages of sepsis, which are as follows:

The sepsis syndrome is recognized clinically by the presence of 2 or more of the following:

Pathophysiology:

Pathogenesis

Sepsis has been referred to as a process of malignant intravascular inflammation. Normally, a potent, complex, immunologic cascade ensures a prompt protective response to microorganism invasion in humans. A deficient immunologic defense may allow infection to become established; however, an excessive or poorly regulated response may harm the host through maladaptive release of indigenously generated inflammatory compounds.

Lipid A and other bacterial products release cytokines and other immune modulators that mediate the clinical manifestations of sepsis. Interleukins, tumor necrosis factor-alpha (TNF-alpha), interferon gamma (IFN-gamma), and other colony-stimulating factors are produced rapidly within minutes or hours after interactions of monocytes and macrophages with lipid A. TNF release becomes a self-stimulating process (an autocrine), and release of other inflammatory mediators, including interleukin-1 (IL-1), platelet activating factor, IL-2, IL-6, IL-8, IL-10, INF, and eicosanoids, further increases cytokine levels. This leads to continued activation of polymorphonuclear leukocytes (PMNs), macrophages, and lymphocytes; proinflammatory mediators recruit more of these cells (a paracrine process). All of these processes create a state of destructive immunologic dissonance.

Sepsis is described as an autodestructive process that permits extension of the normal pathophysiologic response to infection to involve otherwise normal tissues and results in MODS.

Specific organ involvement

Organ dysfunction or organ failure may be the first clinical sign of sepsis, and no organ system is immune from the consequences of the inflammatory excesses of sepsis.

Circulation

Significant derangement in autoregulation of circulation is typical of sepsis. Vasoactive mediators cause vasodilatation and increase the microvascular permeability at the site of infection. Nitric oxide plays a central role in the vasodilatation of septic shock. Also, impaired secretion of vasopressin may occur, which may permit persistence of vasodilatation.

Central circulation: Changes in both systolic and diastolic ventricular performance occur in sepsis. Through the use of the Frank Starling mechanism, cardiac output often is increased to maintain the BP in the presence of systemic vasodilatation. Patients with preexisting cardiac disease are unable to increase their cardiac output appropriately.

Regional circulation: Sepsis interferes with the normal distribution of systemic blood flow to organ systems; therefore, core organs may not receive appropriate oxygen delivery.

Microcirculation is the key target organ for injury in sepsis syndrome. A decrease in the number of functional capillaries causes an inability to extract oxygen maximally, which is caused by intrinsic and extrinsic compression of capillaries and plugging of the capillary lumen by blood cells. Increased endothelial permeability leads to widespread tissue edema of protein-rich fluid.

Redistribution of intravascular fluid volume resulting from reduced arterial vascular tone, diminished venous return from venous dilation, and release of myocardial depressant substances causes hypotension.

Pulmonary dysfunction

Endothelial injury in the pulmonary vasculature leads to disturbed capillary blood flow and enhanced microvascular permeability, resulting in interstitial and alveolar edema. Neutrophil entrapment within the pulmonary microcirculation initiates and amplifies the injury to alveolar capillary membranes. Acute respiratory distress syndrome (ARDS) is a frequent manifestation of these effects.

Gastrointestinal dysfunction and nutrition

The GI tract may help propagate the injury of sepsis. Overgrowth of bacteria in the upper GI tract may be aspirated into the lungs, producing nosocomial pneumonia. The normal barrier function of the gut may be affected, allowing translocation of bacteria and endotoxins into the systemic circulation and extending the septic response. Septic shock usually causes ileus, and the use of narcotics and sedatives delays institution of enteral feeding. The optimal level of nutritional intake is interfered with in the face of high protein and calorie requirements.

Liver

By virtue of the role of the liver in host defense, the abnormal synthetic functions caused by liver dysfunction can contribute to both the initiation and progression of sepsis. The reticuloendothelial system of the liver acts as a first line of defense in clearing bacteria and their products; liver dysfunction leads to a spillover of these products into systemic circulation.

Renal dysfunction

Acute renal failure often accompanies sepsis due to acute tubular necrosis. The mechanism is by systemic hypotension, direct renal vasoconstriction, release of cytokines (eg, TNF), and activation of neutrophils by endotoxins and other peptides, which contribute to renal injury.

Central nervous system dysfunction

Involvement of the CNS in sepsis produces encephalopathy and peripheral neuropathy. The pathogeneses is poorly defined.

Mechanisms of organ dysfunction and injury

The precise mechanisms of cell injury and resulting organ dysfunction in sepsis are not understood fully. Multiorgan dysfunction syndrome is associated with widespread endothelial and parenchymal cell injury because of the following proposed mechanisms:

Coagulopathy

Subclinical coagulopathy signified by a mild elevation of the thrombin or activated partial thromboplastin time (aPTT) or a moderate reduction in platelet count is extremely common, but overt disseminated intravascular coagulation (DIC) is rare. Deficiencies of coagulation system proteins, including protein C, antithrombin 3, and tissue factor inhibitors, cause coagulopathy.

Characteristics of sepsis that influence outcomes

Clinical characteristics that relate to the severity of sepsis include an abnormal host response to infection, the site and type of infection, the timing and type of antimicrobial therapy, the offending organism, and the development of shock, underlying disease, and the patients’ chronic health condition. The location of patient at the time of septic shock also relates to the severity of sepsis.

Frequency:

Mortality/Morbidity: Mortality from multiorgan dysfunction syndrome remains high. Mortality from ARDS alone is 40-50%. Once additional organ system dysfunction occurs, the mortality increases as much as 90%.

CLINICAL

History: Symptoms of sepsis usually are nonspecific and include fever, chills, and constitutional symptoms of fatigue, malaise, anxiety, or confusion. These symptoms are not pathognomonic for infection and may be observed in a wide variety of noninfectious inflammatory conditions. They may be absent in serious infections, especially in elderly individuals.

Physical: Physical examination notes the general condition of the patient first. Observe the overall hemodynamic condition to search for signs of hyperperfusion. Look for signs suggestive of a focal infection. An acutely ill, toxic appearance is a common feature in serious infections.

DIFFERENTIALS

Acute Renal Failure
Acute Respiratory Distress Syndrome
Cardiogenic Shock
Infective Endocarditis
Pneumococcal Infections
Pneumonia, Bacterial
Sepsis, Bacterial
Septic Shock
Shock, Distributive
Shock, Hemorrhagic
Streptococcus Group A Infections
Systemic Inflammatory Response Syndrome
Toxic Shock Syndrome
Urinary Tract Infection, Females
Urinary Tract Infection, Males
Ventilation, Mechanical

WORKUP

Lab Studies:

Imaging Studies:

Procedures:

Staging: Two well-defined forms of multiorgan dysfunction syndrome exist. In both, the development of acute lung injury or ARDS is of key importance to the natural history. ARDS is the earliest manifestation in all cases.

TREATMENT

Medical Care:

Surgical Care: Take patients with infected foci to surgery after initial resuscitation and administration of antibiotics for definitive surgical treatment. Little is gained by spending hours stabilizing the patient when an infected focus persists.

Consultations:

MEDICATION

The proven medical treatments for septic shock are restoration of intravascular volume and broad-spectrum empirical antibiotic coverage. All other medical therapies, while theoretically attractive, have not reduced morbidity or mortality.

Drug Category: Isotonic crystalloids -- Standard fluid used for initial volume resuscitation. These fluids expand the intravascular and interstitial fluid spaces. Typically, approximately 30% of administered isotonic fluid remains intravascular; therefore, large quantities may be required to maintain an adequate circulating volume.
Drug Name
Normal saline (NS) and Ringer lactate (RL) -- Both fluids essentially are isotonic and have equivalent volume restorative properties. While some differences exist between metabolic changes observed with administration of large quantities of either fluid, for practical purposes and in most situations, the differences are clinically irrelevant. No demonstrable difference in hemodynamic effect, morbidity, or mortality exists between resuscitation with either NS or RL. The amount of intravascular fluid requirements are related to the degree of vascular endothelial injury and impaired vasomotor tone; thus, not only may very large quantities of fluids be required initially, but continual fluid resuscitation often is required during the initial days of management of these patients.
Adult Dose 1-2 L initially, with reassessment of hemodynamic response; amounts required during the first few hours typically are 4-5 L
Pediatric Dose Not established
Contraindications Pulmonary edema in which the added fluid promotes more edema and may lead to development of ARDS
Interactions None reported
Pregnancy A - Safe in pregnancy
Precautions Closely monitor cardiovascular and pulmonary function; stop fluids when the desired hemodynamic response is observed or pulmonary edema develops; interstitial edema is a major complication; edema in an extremity is unsightly but not a significant complication; edema in brain or lungs is potentially fatal
Drug Category: Colloids -- Resuscitation fluids used because they provide an oncotically active substance that expands plasma volume to a greater degree than isotonic crystalloids and reduces the tendency to pulmonary and cerebral edema. Approximately 50% of the administered colloid remains intravascular.
Drug Name
Albumin 5% (Albuminar, Albunex) -- Used for treatment of certain types of shock or impending shock. Useful for plasma volume expansion and maintenance of cardiac output.
Solution of normal saline and 5% albumin is available for volume resuscitation.
Adult Dose 250-500 mL over 20-30 min, with reassessment of hemodynamic response
Pediatric Dose Not established
Contraindications Documented hypersensitivity; pulmonary edema; protein load of 5% albumin
Interactions None reported
Pregnancy B - Usually safe but benefits must outweigh the risks.
Precautions No proven benefit of colloid resuscitation over isotonic crystalloids is known; protein load tends to exacerbate renal insufficiency, a potential complication of septic shock; studies document an increased incidence of renal failure in patients with colloid resuscitation
Drug Category: Antibiotics -- Empirical antibiotics that cover the infecting organism and are started early are the only other proven medical treatment for septic shock. In order to provide the necessary coverage, broad-spectrum and/or multiple antibiotics are started. Monotherapy is possible in adults who are not immunocompromised with either antipseudomonal penicillin or a carbapenem. Combination therapy in adults involves 1 of the following: a third-generation cephalosporin plus anaerobic coverage (clindamycin or metronidazole) or a fluoroquinolone plus clindamycin. Administer all initial antibiotics intravenously in patients with septic shock.
Drug Name
Cefotaxime (Claforan) -- Used for treatment of septicemia. Also used for treatment of gynecologic infections caused by susceptible organisms. Third-generation cephalosporin with enhanced gram-negative coverage, especially to Escherichia coli, Proteus species, and Klebsiella species. Has variable activity against Pseudomonas species.
Adult Dose 1-2 g IV q4h
Pediatric Dose Not established
Contraindications Documented hypersensitivity
Interactions Probenecid may decrease cefotaxime clearance, causing an increase in cefotaxime levels; furosemide and aminoglycosides may increase nephrotoxicity when used concurrently
Pregnancy B - Usually safe but benefits must outweigh the risks.
Precautions Adjust dose in severe renal impairment; associated with severe colitis
Drug Name
Ceftriaxone (Rocephin) -- Used because of an increasing prevalence of penicillinase-producing microorganisms. Inhibits bacterial cell wall synthesis by binding to 1 or more of the penicillin-binding proteins. Bacteria eventually lyse due to the ongoing activity of cell wall autolytic enzymes while cell wall assembly is arrested.
Adult Dose 1 g IV q6-12h
Pediatric Dose Not established
Contraindications Documented hypersensitivity
Interactions Probenecid may decrease ceftriaxone clearance, causing an increase in ceftriaxone levels; ethacrynic acid, furosemide, and aminoglycosides may increase nephrotoxicity when used concurrently
Pregnancy B - Usually safe but benefits must outweigh the risks.
Precautions Adjust dose in renal impairment; use with caution in breastfeeding women and in patients allergic to penicillin
Drug Name
Cefuroxime (Zinacef) -- Second-generation cephalosporin that maintains gram-positive activity of the first-generation cephalosporins and adds activity against E coli, Klebsiella pneumoniae, Proteus mirabilis, Haemophilus influenzae, and Moraxella catarrhalis. Condition of the patient, severity of the infection, and susceptibility of the microorganism determine proper dose and route of administration.
Adult Dose 1.5 g IV q8h
Pediatric Dose Not established
Contraindications Documented hypersensitivity
Interactions Alcoholic beverages consumed concurrently within <72 h after taking cefuroxime may produce acute alcohol intolerance (disulfiramlike reaction); hypoprothrombinemic effects of anticoagulants may be increased by cephalosporins with the methyltetrazolethiol side chain (eg, cefuroxime); monitor renal function in patients receiving potent diuretics (eg, loop diuretics), risk of nephrotoxicity may be increased; aminoglycoside nephrotoxicity may potentiate cefuroxime effects in the kidney when used concurrently, monitor renal function closely
Pregnancy C - Safety for use during pregnancy has not been established.
Precautions Administer one half the dose to patients with creatinine clearance of 10-30 mL/min; administer one fourth the dose to patients with a creatinine clearance of <10 mL/min; use of antibiotics for prolonged periods of time or repeated therapy may result in bacterial or fungal overgrowth of nonsusceptible organisms that may lead to a secondary infection, take appropriate measures if superinfection occurs
Drug Name
Ticarcillin/clavulanate (Timentin) -- Antipseudomonal penicillin plus a beta-lactamase inhibitor that provides coverage against most gram-positives (variable coverage against Staphylococcus epidermidis and none against methicillin-resistant Staphylococcus aureus [MRSA]), most gram-negative organisms, and most anaerobes.
Adult Dose 3.1 g IV q4-6h
Pediatric Dose Not established
Contraindications Documented hypersensitivity; severe pneumonia; do not treat bacteremia, pericarditis, emphysema, meningitis, and purulent or septic arthritis with an oral penicillin during acute stage
Interactions Tetracyclines may decrease effects; high concentrations may physically inactivate aminoglycosides if administered in the same IV line; probenecid may increase penicillin levels; effects when administered concurrently with aminoglycosides are synergistic
Pregnancy B - Usually safe but benefits must outweigh the risks.
Precautions Perform CBCs prior to initiation of therapy and at least weekly during therapy; monitor for liver function abnormalities by measuring AST and ALT during therapy; perform urinalysis, BUN, and creatinine determinations during therapy, and adjust dose if these values become elevated; if renal impairment is known or suspected, adjust dose and monitor blood levels; these measures avoid possible neurotoxic reactions
Drug Name
Piperacillin/tazobactam (Zosyn) -- Inhibits the biosynthesis of cell wall mucopeptide and is effective during the stage of active multiplication. Has antipseudomonal activity.
Adult Dose 3.375 g IV q6h
Pediatric Dose Not established
Contraindications Documented hypersensitivity; do not treat severe pneumonia, bacteremia, pericarditis, emphysema, meningitis, and purulent or septic arthritis with an oral penicillin during the acute stage
Interactions Tetracyclines may decrease the effects; high concentrations may physically inactivate aminoglycosides; probenecid may increase penicillin levels; effects when administered concurrently with aminoglycosides are synergistic
Pregnancy B - Usually safe but benefits must outweigh the risks.
Precautions Perform CBCs prior to initiation of therapy and at least weekly during therapy; monitor for liver function abnormalities by measuring AST and ALT during therapy; perform urinalysis, BUN, and creatinine determinations during therapy, and adjust dose if these values become elevated; if renal impairment is known or suspected, adjust dose and monitor blood levels; these measures avoid possible neurotoxic reactions
Drug Name
Imipenem and cilastatin (Primaxin) -- Carbapenem with activity against most gram-positive organisms (except MRSA), gram-negative organisms, and anaerobes. Used for treatment of multiple organism infections in which other agents do not have wide spectrum coverage or are contraindicated due to their potential for toxicity.
Adult Dose 500 mg IV q6h
Pediatric Dose <12 years: Not established
>12 years: Administer as in adults
Contraindications Documented hypersensitivity
Interactions Coadministration with cyclosporine may increase CNS adverse effects of both agents; coadministration with ganciclovir may result in generalized seizures
Pregnancy C - Safety for use during pregnancy has not been established.
Precautions Adjust dose in renal insufficiency; avoid use in children <12 years
Drug Name
Meropenem (Merrem) -- Carbapenem with slightly increased activity against gram-negative organisms and slightly decreased activity against staphylococci and streptococci compared to imipenem.
Adult Dose 1 g IV q8h
Pediatric Dose Not established
Contraindications Documented hypersensitivity
Interactions Probenecid may inhibit renal excretion of meropenem, increasing meropenem levels
Pregnancy B - Usually safe but benefits must outweigh the risks.
Precautions Pseudomembranous colitis and thrombocytopenia may occur, requiring immediate discontinuation of medication
Drug Name
Clindamycin (Cleocin) -- Primarily used for its activity against anaerobes. Has some activity against streptococcus and methicillin-sensitive S aureus (MSSA).
Adult Dose 600-900 mg IV q8h
Pediatric Dose 5-10 mg/kg IV q8h
Contraindications Documented hypersensitivity; regional enteritis; ulcerative colitis; hepatic impairment; antibiotic-associated colitis
Interactions Increases duration of neuromuscular blockade induced by tubocurarine and pancuronium
Pregnancy D - Unsafe in pregnancy
Precautions Dose adjustment may be necessary in severe hepatic dysfunction; no adjustment is necessary in renal insufficiency; associated with severe and possibly fatal colitis
Drug Name
Metronidazole (Flagyl) or Ciprofloxacin (Cipro) -- Metronidazole: Imidazole ring-based antibiotic active against various anaerobic bacteria and protozoa. Usually employed in combination with other antimicrobial agents, except when it is used for Clostridium difficile enterocolitis in which monotherapy is appropriate.

Ciprofloxacin: Fluoroquinolone with variable activity against streptococci, MSSA, S epidermidis, and most gram-negative organisms. No activity against anaerobes.

Adult Dose Metronidazole: Loading dose: Infuse 15 mg/kg over 1 h or 1 g for a 70-kg adult
Maintenance dose: Infuse 7.5 mg/kg over 1 h q6-8h or 500 mg for a 70-kg adult; administer 6 h following the loading dose; not to exceed 4 g in 24 h

Ciprofloxacin: 1400 mg IV q12h

Pediatric Dose Not established
Contraindications Documented hypersensitivity
Interactions Metronidazole: Potentiates anticoagulant effect of warfarin; agents that alter hepatic P450 system affect its clearance; phenytoin and phenobarbital may decrease half-life; may reduce metronidazole clearance and increase toxicity; may increase effect of anticoagulants; may decrease lithium and phenytoin clearance, increasing their toxicity; disulfiramlike reactions may occur when used concurrently with orally ingested ethanol (although the risk for most patients may be slight, exercise caution)

Ciprofloxacin: Antacids, iron salts, and zinc salts may interfere with GI absorption of fluoroquinolones, resulting in decreased serum levels; administer antacids 2-4 h before or after fluoroquinolones; cimetidine may interfere with metabolism fluoroquinolones and reduce therapeutic effects of phenytoin; probenecid may increase ciprofloxacin serum concentrations significantly; ciprofloxacin may increase theophylline and caffeine concentrations and prolong duration of action; may increase nephrotoxic effect of cyclosporine; digoxin serum levels may be increased when used concurrently with ciprofloxacin; monitor digoxin levels; may increase effects of anticoagulants; monitor PT

Pregnancy B - Usually safe but benefits must outweigh the risks.
Precautions Metronidazole: Preganancy catebory B; adjust dose in patients with severe hepatic disease because they may metabolize metronidazole slowly; monitor patients for seizures and the development of peripheral neuropathy

Ciprofloxacin: Pregnancy category C; in prolonged therapy, perform periodic evaluations of organ system functions, including renal, hepatic, and hematopoietic; patients diagnosed with renal function impairment may require a dose adjustment; prolonged or repeated antibiotic therapy may result in bacterial or fungal overgrowth of nonsusceptible organisms, resulting in secondary infections; take appropriate measures to prevent further complications

Drug Category: Activated Protein C analogs -- Exert antithrombic effects, have indirect profibrinolytic activity, and may have anti-inflammatory effect.
Drug Name
Drotrecogin alfa (Xigris) -- Indicated for reduction of mortality in patients with severe sepsis associated with acute organ dysfunction and at high risk of death. Recombinant form of human activated protein C that exerts antithrombotic effect by inhibiting factors Va and VIIIa. Has indirect profibrinolytic activity by inhibiting plasminogen activator inhibitor-1 (PAI-1) and limiting formation of activated thrombin-activatable-fibrinolysis-inhibitor. May exert anti-inflammatory effect by inhibiting human tumor necrosis factor (TNF) production by monocytes, blocking leukocyte adhesion to selectins, and limiting thrombin-induced inflammatory responses within microvascular endothelium.
Adult Dose 24 mcg/kg/h IV continuous infusion for 96 h; ideally, initiate within 48 h of sepsis onset
Pediatric Dose Not established
Contraindications Documented hypersensitivity; increased risk of bleeding (eg, active internal bleeding, recent hemorrhagic stroke, recent intraspinal or intracranial surgery, recent or current trauma, presence of epidural catheter, intracranial neoplasm, cerebral herniation, severe head trauma)
Interactions None reported; coadministration with drugs that affect hemostasis may increase risk of bleeding (eg, warfarin, heparin, thrombolytics, glycoprotein IIb/IIIa inhibitors)
Pregnancy C - Safety for use during pregnancy has not been established.
Precautions Bleeding is most common serious adverse effect; caution with conditions that increase risk of bleeding including INR >3, concurrent therapeutic heparin (>15 U/kg/h), within 6 wk of GI bleeding episode, within 3 d of thrombolytic therapy, within 7 d of platelet inhibitors administration, within 3 mo of ischemic stroke, intracranial arteriovenous malformation or aneurysm, known bleeding diathesis, chronic severe hepatic disease; stop infusion if clinically significant bleeding occurs
Drug Category: Vasopressor supportive therapy -- If patient does not respond to several liters of isotonic crystalloid (usually 4 or more) or evidence of volume overload is present, the depressed cardiovascular system can be stimulated by inotropic and vasoconstrictive agents.
Drug Name
Dopamine (Inotropin) -- Used to treat hypotension in fluid-resuscitated patients. Stimulates both adrenergic and dopaminergic receptors. Hemodynamic effect depends on the dose. Lower doses stimulate mainly dopaminergic receptors that produce renal and mesenteric vasodilation in health volunteers, but probably have no measurable effect in patients who are critically ill. Higher doses produce cardiac stimulation, tachycardia, and vasoconstriction.
Adult Dose In hypotensive hyperdynamic shock: starting dose of 2-5 mcg/kg/min; titrate as needed to maintain a MAP >60 mm Hg; may be increased by 1-4 mcg/kg/min q10-30min until satisfactory response; not to exceed 20 mcg/kg/min
Maintenance dose: <20 mcg/kg/min usually are adequate for 50% of patients treated
Pediatric Dose Not established
Contraindications Documented hypersensitivity; tachycardia; pheochromocytoma; ventricular tachyarrhythmias
Interactions Phenytoin, alpha-adrenergic and beta-adrenergic blockers, general anesthesia, and MAO inhibitors increase and prolong the effects
Pregnancy C - Safety for use during pregnancy has not been established.
Precautions Monitor urine flow, cardiac output, pulmonary wedge pressure, and BP closely during the infusion; prior to infusion, correct hypovolemia with either whole blood or plasma, as indicated; monitoring of central venous pressure or left ventricular filling pressure may be helpful in detecting and treating hypovolemia
Drug Name
Norepinephrine (Levophed) -- As with dopamine, it is used to treat hypotension following adequate fluid-volume replacement. Norepinephrine stimulates beta 1-adrenergic and alpha-adrenergic receptors, which increase arterial tone and cardiac contractility. As a result, systemic BP and coronary blood flow increases with norepinephrine, though myocardial oxygen demand also may increase. After obtaining a response, adjust infusion rate to maintain a MAP greater than 60 mm Hg. BP levels below this threshold are insufficient to perfuse vital organs while increasing pressures much greater than 70 mm Hg, using vasopressors does not further increase tissue blood flow.
Adult Dose 0.05-2 mcg/kg/min IV; titrate to effect
Pediatric Dose Not established
Contraindications Documented hypersensitivity; known hypovolemia; peripheral or mesenteric vascular thrombosis because ischemia may be increased and the area of the infarct extended
Interactions Atropine sulfate may enhance pressor response of norepinephrine by blocking reflex bradycardia caused by norepinephrine
Pregnancy D - Unsafe in pregnancy
Precautions Correct blood-volume depletion, if possible, before administering norepinephrine therapy; extravasation may cause severe tissue necrosis, administer into a large vein; use with caution in patients with occlusive vascular disease
Drug Name
Vasopressin (Pitressin) -- Has vasopressor and antidiuretic hormone (ADH) activity. Although vasopressin does not increase BP in healthy subjects, it markedly increases vasomotor tone in patients with septic shock. It also increases water resorption at the distal renal tubular epithelium (ADH effect) and promotes smooth muscle contraction throughout the vascular bed of the renal tubular epithelium (vasopressor effects). Vasoconstriction also is increased in splanchnic, portal, coronary, cerebral, peripheral, pulmonary, and intrahepatic vessels. Vasopressin is not yet routinely used to treat hypotension in septic shock. The dosage of vasopressin used for hypotension is one-tenth that used to treat upper GI bleeding from varices.
Adult Dose Suggested dose: 0.01-0.05 U/min; titrate dose as needed
Pediatric Dose Not established
Contraindications Documented hypersensitivity; coronary artery disease
Interactions Lithium, epinephrine, demeclocycline, heparin, and alcohol may decrease the effects of vasopressin; conversely, chlorpropamide, urea, fludrocortisone, and carbamazepine potentiate its effects
Pregnancy B - Usually safe but benefits must outweigh the risks.
Precautions Caution in cardiovascular disease, seizure disorders, nitrogen retention, asthma, or migraine; excessive doses may result in hyponatremia

FOLLOW-UP

Further Inpatient Care:

Transfer:

Deterrence/Prevention:

Prognosis:

MISCELLANEOUS

Medical/Legal Pitfalls:

Special Concerns:

Home page, Drug information's ,Regional anesthesia ,Index for  diseases ,Index for  diseases, Perioperative medicine, Search engine, Accreditation, Learn Arabic Warfare, Anesthesia LINKS, Orthopedic LINKS, Midline

Constructed by Dr N.A. Nematallah Consultant in perioperative medicine and intensive therapy, Al Razi Orthopedic Hospital , State of Kuwait, email : razianesth@freeservers.com